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Summary 
Many human tumor ceils have been shown to express antigens that are recognized by autolo- 
gous cytotoxic T lymphocytes (CTL) and the molecular nature era number of melanoma anti- 
gens has been defined recendy. Here we describe the characterization of an antigen recognized 
on a renal ceil carcinoma by autologous CTL clones. This antigen is encoded by the HLA-A2 
gene present in the tumor cells. The sequence of this gene differs from the HLA-A2 sequence 
found in autologous peripheral blood lymphocytes by a point mutation that results in an argi- 
nine to isoleucine exchange at residue 170, which is located on the a-helix of the ct2 domain. 
Transfection experiments with the normal and mutated HLA-A2 cDNA demonstrated that this 
amino  acid  replacement was  responsible  for the  recognition of the  HLA-A2  molecule  ex- 
pressed on the tumor cells. The mutant HLA-A2 gene was also detected in the original tumor 
tissue from the patient, excluding the possibility that the mutation had appeared in vitro. Thus, 
HLA class I molecules carrying a tumor-specific mutation can be involved in the recognition of 
tumor cells by autologous CTL. 
I 
n the last five years, knowledge of human tumor antigens 
.recognized by autologous CTL has 'increased consider- 
ably. So far,  genetic and biochemical approaches have led 
to the molecuhr identification of three classes of antigens, 
The first class comprises antigens encoded by genes that are 
expressed in various tumors of different histological origins, 
but not in normal tissues other than testis, such as MAGE-1 
(1, 2), MAGF.-3  (3),  BAGE (4),  and  GAGE-l~2 (5). The 
second class represents differentiation antigens encoded by 
genes  that  are  only  expressed  irt  melanoma  and  normal 
melanocytes,  like  tyrosinase  (6),  Melan-A  MAr~T-t  (7,  g), 
glgI00  P'mt'll7 (9,  10),  and ~75 TRy) (11).  The third class in- 
cludes antigens produced by unique point mutations in genes 
that are ubiquitously expressed, such  a~ MUM. I  (I2)  and 
CDK4 (13).  In both cases, the antigenic peptide is encoded 
by the mutated region of the gene, 
Both renal cell carcinoma 0a.CC) ~  and melanoma are con- 
sidcred potentially immunogcnic in humans, Both types of 
tumor  are often infiltrated by T  lymphocytes, and  m￿9 
static lesions werr  found to re~ress spontaneously in a small 
but significant number of ca~s  (14-18).  Durable  tumoral 
responses were observed afar IL-2 treatment in 15~20% of 
cases, and some of therrt may result from the elicitation of 
tAbbte~iations uged in thi~ paper: KCC, renal Cell c~rciho~a; g.ql', teVcrge 
Ifamcril~tOn. 
T  cell responses (19, 20). This suggests  that kidney tumors, 
like melanomas, express antigens that can be recognized by 
autologom T  lymphocytes. However,  our knowledge  of 
tumor-specific  antigens  expressed  on  ILCC  is  scarce.  In 
contrast to melanoma, it proved difficult to adapt RCC to 
in  vitro  culture  conditions,  and  to  generate  stable  CTL 
clones for the identification of antigens present on this type 
of tumor. In addition, genes MAGE-1,  MAGE-3,  BAGE, 
and  GAGE-l~2  are  expressed in  various tumors  but  not 
in I~CC, 
Here we  report the  identification of an  antigen that  is 
recognized by autologous CTL on human  KCC  cell line 
LB996~RCC. The antigen is encoded by a mutated HLA- 
A2 genr 
Matedals  and  Methods 
Cell Lines,  I~CC cell line LB996-KCC was derived from the 
primary tumor of 6%yr-old Caucasian patient LB996 (HLA-A2, 
-A11, -B18,  -B44,  -CwI, and -.Cw*1601) and grown as previ- 
ously described (21). This patient died of  pulmonary embolism 7 wk 
after ngphrectomy for a stage II1 KCC that invaded the inferior 
verla eava, Lymphoblastoid  cell line  LB996-EDV was  derived 
from the  PDL oa  e lratient  LB996 by standard techniques,  GTL 
glone 314/4 w;t~ det'ived from LD996~PBL  which were ,tirrtulatod 
in vitro with itr~glia~d atatologous LB996-P, CC gellL This CTL 
clone expre~ed both CD4 and CD8 molecules. Other CTL clones 
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against HLA-A*0201-R170I (data not shown). RFLP analysis con- 
firmed that LB996-ILCC and LB996-PBL  originated from the 
same patient (data not shown). HeLa-S3 cells were obtained from 
the American Type Culture Collection (Rockville, MD).  They 
were  transfected  by the  calcium phosphate  precipitate  method 
with HLA-A*O201-R170I or HLA-A*0201  cDNA cloned indi- 
vidually into plasmid pcDNA3 (Invitrogen Corp., San Diego, CA) 
which contains the neomycin resistance gene. Clonal sublines were 
isolated from transfected populations resistant to G418 (2 mg/ml). 
Cytotoxicity Assay.  The lyric activity of CTL was tested  in a 
chromium  release  assay  as  previously  described  (22). Briefly, 
1,000  chromium-labeled cells in 100 Ixl were incubated in 96- 
well microplates with an equal volume of CTL at different effec- 
tot to target ratios. Chromium release was measured  after 4 h of 
incubation. 
CTL Stimulation Assay.  2,500 CTL were added to microwells 
containing stimulator cells in 100 pA of lscove medium (GIBCO 
BRL, Gaithersburg,  MD) supplemented with 10% human serum 
and 25 U/ml r-hu-IL-2. After 18 h, the supernatant was collected 
and its TNF content determined by testing the cytotoxic effect 
on WEHI-164 clone 13 cells (23) in a MTT colorimetric assay 
(24). Inhibition with rnAbs W6/32 (anti-HLA class I; 25), L243 
(anti-HLA-DR; 26),  BB7.2  (anti-HLA-A2; 27),  B.9.4.1  (anti- 
CD8),  and 13B8.2  (anti-CD4) (donated by Dr.  D.  Olive, IN- 
SERM Ul19, Marseille, France) was performed by addition of a 
1/20 dilution ofascites to the test. 
Construction of the eDNA Library.  Total ILNA was extracted by 
the guanidine-isothiocyanate  procedure (28) from LB996-RCC 
cells that  had  undergone 25  in vitro passages after  surgical  re- 
moval  from  patient  LB996.  Poly(-A)  +  ILNA  enriched  by  an 
oligo(dT)-cellulose column was converted to cDNA with the Su- 
persctipt Choice System (GIBCO BILL) using an ofigo(dT) primer 
containing a Notl site at its 5'  end. The eDNA was ligated  to 
BstXI  adaptors,  digested  with Notl, and inserted into the BstXI 
and NotI sites of expression vector pcDNA3. Recombinant plas- 
nfids  were  electroporated  into Escherichia coli Topl0F'  and se- 
lected with ampicillin (100 p~g/ml). The library was divided into 
400 pools of 100 eDNA clones. Each pool of bacteria was ampli- 
fied  to  saturation  and  plasmid  DNA  was  extracted  using the 
QIAprep 8 plasmid kit (Qiagen GmbH, Hilden, Germany). 
Transfection of  COS-7  Cells for  Screening the  cDNA  Library. 
Transient transfection was  performed  by  the  DEAE-dextran- 
chloroquine method (29). Briefly,  1.5  ￿  104 COS-7 cells were 
transfected  with  100 ng of plasmid DNA from a pool from the 
eDNA library,  and 100 ng of plasmid  pcDNA3 containing the 
HLA-A*0201 gene that was derived from an unrelated individual 
(30). Transfected  COS-7 cells were tested  in a CTL stimulation 
assay after 48 h. 
Cloning of the HLA-A2 cDNA fiom LB996-PBL.  Total RNA was 
extracted  from LB996-PBL  by the guanidine-isothiocyanate  pro- 
cedure (28). Reverse transcription (ILT) was performed on 2 p,g 
of total RNA in a 20-I.tl reaction volume containing 4 I.tl of 5￿ 
reverse transcriptase buffer (GIBCO BRL), 1 I-tl each of 10 mM 
dNTP, 2 ILl ofa 20-~zM solution of oligo(dT)15 primer, 20 U  of 
ILNasin  (Promega  Corp., Madison, WI), 2  ILl of 0.1  M  dithio- 
threitol,  and 200  U  of Moloney murine leukemia virus reverse 
transcriptase (GIBCO BILL). The reaction was incubated at 42~ 
for 60 rain. One-twentieth of the cDNA product was then sup- 
plemented with 10 I-tl of 10￿  polymerase buffer, 2 ~1 each of 10 
mM dNTP, 5 ~zl each of 20 p.M primer solutions,  2.5 U of PFU 
DNA polymerase  (Stratagene  Inc., La Jolla,  CA)  and water to a 
final volume of 100 Ixl. PCR amplification was carried out using 
forward  primer 5'-GGCGAATTCGGACTCAGAATCTCCCC- 
AGACGCCGAG and reverse  primer 5'-CCCGAATTCTCT- 
CAGTCCCTCACAAGGCAGCTGTC  that hybridize to the 5' 
and 3' untranslated regions of all HLA class I genes respectively, 
and that both contain an EcoRI site (31). An initial denaturation 
step was performed for 4 rain at 94~  followed by 30 cycles (1 rain 
at 94~  5 s at 62~  and 3 rain at 75~  and 5 additional cycles 
(1  n-fin at 94~  5 s at 62~  and 5 rain at 75~  The amplifica- 
tion finished with  10 min at  75~  The PCIL  product was di- 
gested with EcoRI and inserted into the EcoRl site ofpcDNA3. 
DNA Sequence Analysis.  DNA sequencing was performed by 
the dideoxy-chain termination method (T7 Sequencing Kit; Phar- 
macia, Uppsala, Sweden)  using specific oligonucleotides as prim- 
ers. The computer search for sequence homology was performed 
with the blast@ncbi.nlm.nih.gov,  program,  (National Library of 
Medicine, NIH, Bethesda, MD). 
PCR Amplification of HLA-A*020 I-R 1701 and HLA-A*0201 
Gene Sequences.  Total RNA extraction, conversion to eDNA, and 
PCR amplifications  were performed as described  in a previous 
section with minor modifications;  1 U  of DynaZyme  TM  (Finn- 
zymes OY, Espoo, Finland) instead of PFU DNA polymerase was 
used.  Amplification  of  the  HLA-A2*O201-R170I  gene  was 
carried out over 31 cycles (30 s at 94~  30 s at 63~  and 1 rain 
at 72~  and that of the HLA-A*0201  gene was performed for 
32 cycles (30 s at 94~  30 s at 64~  and 1 min at 72~  using 
either  reverse  primer  5'-CCTTCCCGTTCTCCAGGTATA, 
corresponding to  nucteotides 581-601  of HLA-A*O201-R1701, 
or 5'-CTTCCCGTTCTCCAGGTAT__C,  corresponding to nu- 
cleotides  581-600  of HLA-A*0201,  respectively,  and  forward 
primer  5'-GGACGGGGAGACACGGAAA, corresponding to 
nucleotides 252-270 of both genes.  The underlined nucleotides 
of the reverse primers determine the sequence specificity. 
Cytofluorometric Analysis.  5 ￿  105 cells were stained in 100 I.t] 
of PBS containing 3% FCS and 20 mM NaN3 for 10 man at 4~ 
for each step. The following antibodies were used: FITC-conju- 
gated  goat anti-mouse Ig (Becton Dickinson & Co.,  Mountain 
View,  CA), HLA-A2-specific mAbs CRll-351 (32) and MA2.1 
(33), BB7.2  (27) and PA2.1  (34). Cells were analyzed on a FAC- 
Scan  |  (Becton Dickinson &  Co.)  using four logarithmic scales. 
Data were only collected from viable cells gated by a combination 
of forward light scatter and 90  ~ side scatter. 
Results 
CTL Clones Specific  for RCC Cell Line LB996oRCC.  By 
stimulating PBL  from patient LB996  with  irradiated cells 
from  autologous  RCC  line LB996-RCC,  we  isolated  a 
panel of CTL clones that specifically lysed the tumor cells, 
but not an autologous EBV-transformed B  cell line or NK 
cell target K562. Results obtained with representative CTL 
clone 314/4 are shown (Fig. 1 A). 
CTL clone 314/4 produced TNF when stimulated with 
LB996-RCC cells, and this TNF production was blocked 
by a mAb that binds to all HLA class I molecules (Fig. 1 B). 
Partial inhibition of TNF production was also observed in 
the presence of mAbs directed against HLA-A2 or against 
CD8,  suggesting  that  the  target  antigen is  presented  by 
HLA-A2. 
Identification  of a cDNA  Coding for the Antigen Recognized 
by CTL314/4.  To  clone  the  gene  conferring recogni- 
tion by  CTL  314/4,  we  prepared  a  cDNA  library from 
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Figure  1.  Specificity of CTL 314/4.  (A) Specific lysis of autologous 
LB996-RCC  cells by CTL 314/4.  LB996-P,  CC cells, autologous EBV- 
transformed lymphoblastoid hne LB996-EBV, and NK cell~sensitive  line 
K562 were used as target cells. Chromium release was measured after 4 h. 
(B) Recognition ofLB996-P, CC cells  by CTL 314/4 is inhibited by anti- 
HLA class  I, anti-HLA-A2 and anti-CD8 mAbs. LB996-P,.CC cells were 
used to stimulate CTL 314/4 in the presence of mAbs with the specifici- 
ties indicated. After 18 h of cocuhure, production of TNF by CTL 314/4 
was measured by testing toxicity of the supematants for TNF-sensitive 
WEHI-  164.13 cells. 
RNA  of LB996-RCC  cells in expression vector pcDNA3. 
We divided the library into 400  pools of 100 bacteria and 
transfected  duphcate  microcultures  of COS-7  cells  with 
DNA  from  each pool together with  a  plasmid coding for 
HLA-A*0201. We tested the transfected cells 48 h  later for 
their ability to induce TNF  release by CTL  314/4.  Three 
cDNA pools proved positive. By subcloning one of them, 
we isolated three cDNA clones that transferred the expres- 
sion of the antigen recognized by CTL  314/4.  The result 
of representative cDNA clone 3B10 is shown (Fig. 2). Sur- 
prisingly, the expression of HLA-A*0201 was not necessary 
as COS-7 cells transfected with clone 3B10 alone were able 
to stimulate TNF production. 
A  Mutated HLA-A2 Molecule is Recognized  by RCCospe- 
cific CTL Clone 314/4.  The  finding  that  the  product  of 
cDNA 3B10 alone was recognized by CTL 314/4  (Fig. 2), 
and the capacity ofanti-HLA-A2 mAbs to block the recog- 
nition ofLB996-P, CC cells by CTL 314/4  (Fig. 1 B) indi- 
cated  that  cDNA  3B10  itself might  code  for  a  HLA-A2 
molecule.  In  fact,  the  sequence  of cDNA  3B10  proved 
identical to that of HLA-A*0201 with the exception of one 
LB996-RCC 
COS 
COS + HLA-A*0201 
COS + HLA-A*0201 
+ 3B10 
COS + 3B10 
I 
I 
~>120 
￿9  --  |.,  ,=-,  -i...I-  ,,i  -  ,.i 
0  20  40  60  80  100  120 
TNF releau by CTL 314/4 (pg/ml) 
Figure 2.  Stimulation of CTL 314/4 by COS-7 cells transfected with 
cDNA clone 3B10. COS-7 cells were transiently transfected with the in- 
dicated cDNA cloned individually into pcDNA3. HLA-A*0201 cDNA 
was previously cloned from an unrelated individual and cDNA 3B10 was 
cloned from LB996-R.CC cells. After 18 h of coculture with transfected 
cells, production of TNF by CTL 314/4 was measured by testing toxicity 
of  the supematants for TNF-sensitive WEHI-164.13 cells. Control stimu- 
lator cells  included autologous LB996-/LCC and untransfected COS-7 cells. 
nucleotide: the guamne (G) at position 581  of HLA-A*0201 
was replaced by a thymine (T), which resulted in an argin- 
ine (R) to isoleucine (I) exchange at residue 170 (Fig.3 A). 
Accordingly, the amino acid replacement was referred to as 
R170I,  and the HLA-A2 gene  expressed by LB996-RCC 
cells was named HLA-A*O201-R170I. As shown in Fig. 4, 
residue 170 is located on the o~-helix of the r  domain. 
This  new  HLA-A2  sequence  did  not  correspond  to  a 
previously described HLA-A2 allele. Therefore,  to  deter- 
mine  whether  HLA-A*0201-tL170I  represented  a  new 
HLA-A2 allele, or resulted from a somatic point mutation 
in tumor LB996-RCC,  we analyzed the corresponding se- 
quence  in normal cells from the same patient.  We ampli- 
fied by R.T-PCtL the coding region of the HLA-A2 gene 
expressed by PBL LB996-PBL,  and cloned it into  expres- 
sion vector pcDNA3. This HLA-A2 sequence proved iden- 
tical to that of HLA-A*0201, thus differing from the HLA- 
A*O201-R170I sequence by one nucleotide (Fig. 3, A  and 
B).  Since patient LB996 was HLA-typed A2 and All,  the 
two HLA-A2 sequences could not represent two alleles of 
the HLA-A2 locus. We concluded that the R170I replace- 
ment was created by a somatic mutation in the tumor cells. 
To confirm the role of this mutation in creating the anti- 
gen recognized by CTL 314/4, we transfected COS-7 cells 
with  plasmids  containing  the  HLA-A2  sequence  isolated 
either from LB996-PBL or from tumor cells LB996-RCC. 
As  shown  in  Fig.  5  A,  CTL  314/4  only produced  TNF 
when  stimulated with  COS-7  cells  that  expressed  HLA- 
A*0201-R170I.  The  possibility that  the  high  replication 
rate of the transfected HLA-A2 genes in COS-7 cells caused 
nonspecific  stimulation  of  CTL  314/4  was  further  ex- 
cluded by the finding that HeLa cells stably transfected with 
HLA-A*O201-R170I  cDNA  were  lysed by  CTL  314/4, 
whereas  stable  HeLa  transfectants  expressing  the  HLA- 
A*0201 cDNA were not (Fig. 5 B). 
Autologous EBV-transformed B  cells pulsed with different 
peptides derived from the mutant region of HLA-A*0201- 
tL170I were not recognized by CTL 314/4, suggesting that 
2503  Br~indle  et al. Figure 3.  A point mutation leads to an amino acid exchange in the coding region of the HLA-A2 gene expressed by LB996-RCC cells. (A) Alignment 
of the partial nucleotide sequence and the deduced protein sequence of HLA-A*0201  (top) in relation to the mutation occurring in LB996-RCC cells 
(bottom). The sequence of the HLA-A2 cDNA cloned from LB996-PBL is identical  to that of HLA-A*0201.  The G to T  transition at  position 581  of 
HLA-A'0201 leads to an argmine to isoleucine  exchange at residue  170; correspondingly,  the mutated gene is named HLA-A*O201-R170I.  (B) Repre- 
sentauve autoradiography  showing the sequence ladder around nucleotide 581 of the HLA-A2 cDNA from LB996-R.CC cells and LB996-PBL.  Plasmids 
pcDNA3 containing the HLA-A2 cDNA cloned from either RCC (le~) or PBL (right) were sequenced by the dideoxy-chain termination method using 
oligonucleotide 5'-AAGGATTACATCGCC (nucleotides  433 to 447 ofgene HLA.A2) as primer. The G (PBL) to T (RCC) tramition at position 581 is 
indicated by the arrow. 
the  CTL recognizes the  altered  HLA-A2  molecule  itself 
rather than a mutant peptide presented by autologous MHC 
molecules (data not shown). 
The  R  1701 Mutation  Occurred  In  Vivo.  To  determine 
whether  the R170I mutation was already present in the orig- 
inal  tumor  tissue  or  whether  it  was  generated  in  vitro  in 
LB996-RCC  cells,  we  designed  specific  primers  to  selec- 
tively amplify by PCR  either the  normal  HLA-A*020I  or 
the  mutated  sequence.  Whereas  LB996-PBL  and  the  cul- 
tured  LB996-RCC  cell  line  only  contained  the  wild-type 
or the mutated sequence respectively, both sequences were 
found  in  the  initial tumor  tissue  (Fig.  6),  The  weak  signal 
for the wild-type gene is probably due to some normal cells 
that  were  surgically  removed  together  with  the  tumor 
Figure 4.  Schematic representation of the structure of HLA-A2. The 
position of residue  170 (closed circle) which is altered in LB996-1LCX~ is in- 
d4cated (arrow). (open circles) The positions  previously  known to be impor- 
tant for binding ofmAb MA2.1. 
mass.  The  strong band  for the  mutated  sequence  clearly 
shows that the mutation occurred in vivo. 
To  examine  whether  the  tL170I  mutation  occurs  fre- 
quently, 34 HLA-A2+ tumor samples  of different histolog- 
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Figure 5.  HLA-A'0201-P,.1701  is reco~caized by CTL 314/4. (A) Stim- 
ulation of CTL 314/4 by COS-7 cells tramfected with phsmid pcDNA3 
containing the  HLA-A'0201-R 1701 cl)NA.  The  I-fLA-A*0201-R  1701 
cDNA was cloned from a cl)NA library  of LB996-1~CC ceils, whereas 
the HLA-A'0201 cl)NA was cloned from LB99O-PBL by RT-PCR us- 
ing HLA  class l~pecific oligonucleotides as  described in  Materials  and 
Methods. Production of TNF by CTL 314/4 was measured as described 
in Fig. 2.  (B) Specific  lysis by CTL 314/4 of HcLJ r  expressing  the 
HLA-A'0201-R 1701 cDNA. HeLa cells gtahly tt"atfftugted  Wl~h either the 
HLA-A*O20t-RI70I  or  the  HLA-A*0201  eDNA  were  used  as  target 
cells. Chromium release was measured after 4 h. The HeLa t~ansfectants 
expressed the same density of HLA-A2 molecules at the cell surface a~ an- 
alyzed by flow cytometry with mAb CRI 1-351  (data not shown). 
2504  A Mutated HLA-A2 Molecule Expressed on a Human Renal Cell Carcinoma Figure 6.  Detection of the point mutation by 1KT-PCR  in the original 
tumor sample of  patient LB996. Total RNA isolated from cultured LB996- 
1KCC cells, from the  original LB996-1KCC tumor  sample, and  from 
LB996-PBL  was subjected to IKT. The resulting cDNA products  were used 
as  templates for  selective PCIK amplification of HLA-A*O201-R170I 
(lanes 1-6) or HLA-A*0201 (lanes 7-12). RNA integrity was checked by 
RT and amplification of 13-actin mlKNA (lanes 13-16). Control templates 
included plasmid pcDNA3  (25  pg)  containing cDNA HLA-A*O201- 
R1701 or HLA-A*0201. 
ical origins were screened by RT-PCR.  All samples proved 
negative for the mutated sequence (data not shown). 
Recognition  of the Mutated  HLA-A*0201  Molecule  by  mAbs. 
To  examine  the  influence  of the  R170I  mutation  on the 
structure  of the  HLA-A*0201  molecule,  a panel  of HLA- 
A2-specific mAbs was used to detect altered antibody bind- 
ing  sites  by  flow  cytometry.  Whereas  mAbs  C1Lll-351, 
BB7.2,  and  PA2.1  stained  lymphocytes  of patient  LB996 
with  the  same  intensity  as  the  RCC  fine,  the  binding  of 
mAb  MA2.1  was  strongly reduced  on  LB996-RCC  cells 
when compared with autologous lymphocytes (Fig. 7). Al- 
though the binding site ofmAb MA2.1 has previously been 
mapped to residues 62-66 on the a-helix of the e~l  domain 
(35),  the finding that residue  170, which is located on the 
a-helix of the or2 domain, also affects binding ofMA2.1, is 
in agreement with a previous report (36), and suggests that 
the epitope is not limited to the oil  helix (Fig. 4). 
Discussion 
The ability of point mutations to generate  new antigens 
recognized by T  cells  was first demonstrated by the analysis 
of turn- antigens, which appear on mouse tumor cells  after 
in vitro  mutagenesis  (37).  These mutations  occur in genes 
expressed ubiquitously, and the resulting amino acid substi- 
tutions generate new antigenic peptides,  either by creating 
an agretope enabling the mutated peptide to bind to MHC 
molecules,  or by creating  a  new  epitope  in  a  peptide  al- 
ready able to bind (38). This mechanism was later found to 
be responsible  for the presence  of T  cell antigens  on both 
murine  and human tumors,  in the absence  of any in vitro 
mutagenesis (12, 13, 39, 40). So far, all tumor antigens gen- 
erated by point mutations  correspond to mutated peptides 
presented by MHC molecules. 
The  antigen  described  here  also  results  from  a  tumor- 
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Figure 7.  Effect  of the arginine to isoleucine exchange at residue 170 
of HLA-A*0201 on the binding of HLA-A2-specific  mAbs. Autologous 
lymphocytes  represented by CTL 314/4 (top) and LB996-1KCC  cells (bot- 
tom) were incubated with mAbs C1Kll-351 (thin line) or MA2.1 (thick 
line), respectively. After washing, the cells were incubated with FITC- 
conjugated goat anti-mouse Ig antibodies, washed again, and analyzed  on a 
FACScan  |  using four logarithmic scales. (dashed lines) Negative control 
stainings using the fluorescent conjugate alone are shown. Binding of 
mAbs BB7.2 and  PA2.1 was identical to that of CRll-351  (data not 
shown). 
specific point mutation.  However,  this  mutation  does  not 
create a new antigenic peptide, but rather modifies the struc- 
ture  of the  HLA-A2 molecule  which  now  appears  to  be 
recognized per se.  The  ability  of altered  MHC  molecules 
to  act as  tumor-specific  antigens  has  been  extensively  de- 
bated,  starting with observations by Invernizzi and Parmi- 
ani  (41,  42).  The  mutated  HLA-A2  molecule  described 
here is the first instance of a somatic point mutation chang- 
ing  an  amino  acid  in  a  MHC  class  I  molecule,  thereby 
transforming it into a target structure that is recognized by 
autologous CTL. Because this mutation is present in tumor 
cells  and  not  in  autologous  normal  cells,  the  antigen  is 
strictly tumor specific and therefore represents  an ideal tar- 
get for cancer immunotherapy.  On  the  other hand,  since 
the mutation, and consequently the antigen, are unique to an 
individual  tumor,  no  vaccine  of general  use  can be  based 
on it. 
The structural basis for recognition of the altered HLA- 
2505  BrSndle et al. A2 molecule  by the  TCR  is  not  clear:  either  the  mutant 
HLA-A2 binds a different set of endogenous peptides,  one 
of which is recognized by the receptor, or the receptor in- 
teracts  directly  with  the  altered  HLA-A2 molecule  inde- 
pendently  of a  specific  peptide.  Preliminary  experiments 
suggest that acid elution of peptides bound to HLA mole- 
cules  of LB996-RCC  cells  does not  affect recognition  by 
CTL 314/4, whereas recognition by a control CTL was re- 
duced  (data  not  shown).  This  observation would  tend  to 
favor the last hypothesis. 
This  antigen  appears  to  be  strongly  immunogenic  in 
vitro, since all 25 LB996-RCC-specific CTL clones that were 
isolated recognized HLA-A*0201-R170I (data not shown). 
Since  patier!t  LB996  did  not reject  his  tumor,  one  might 
ask why he failed to mount an effective antitumor immune 
response in vivo. There are several possible explanations of 
the paradox of in vitro measurable  CTL reactivity without 
tumor response in vivo. First,  tumor-specific T  cells  might 
be present in vivo but unresponsive.  This might be due to 
the  absence on tumor cells  of costimulatory molecules re- 
quired for efficient stimulation  of T  cells  (for a review see 
reference 43). T  cells infiltrating kidney tumors were shown 
to express reduced levels of the TCR  ~ chain, which might 
partly explain  the  unresponsiveness  resulting from incom- 
plete stimulation with tumor antigens (44, 45). Such T  cells 
could,  however,  respond in vitro  in the  presence  of lym- 
phokines  replacing  the  missing  costimulatory  signal.  The 
finding  that  costimulation  of CD8 +  T  cells  by B7-trans- 
fected  melanoma  cells  resulted  in  tumor  rejection  in  two 
mouse  models  supports  the  importance  of providing  two 
signals to T  lymphocytes (46,  47).  Another reason for the 
absence of an effective antitumor response in vivo could be 
the selective deletion of tumor-specific high-avidity T  cells 
due to the presence of the tumor. Similar to observations in 
spleen-chimeric  mice  (48),  and  in  H-2  transgenic  mice 
(49),  it  is  possible  that  the  remaining  low-avidity  T  cells 
lack potent functional  activity in vivo, but  can respond in 
vitro under appropriate stimulatory conditions, leading to a 
state of split tolerance. 
Regardless  of the  mechanism underlying the  unrespon- 
siveness  in vivo,  it  may be  possible  to  immunize  patients 
against mutated antigens by using presentation by dendritic 
cells,  or by injecting the antigen together with adjuvants or 
lymphokines.  Although  unique  antigens  are  restricted  to 
individual  tumors,  their  exquisite  tumor specificity would 
make them very safe targets for such active immunizations. 
In addition, transplantation studies with chemically induced 
mouse  tumors  have  shown  that  unique  antigens  can  be 
very strong immunogenic rejection antigens  (38,  50).  The 
observation  that  tumor  cells  are  frequently  deficient  in 
DNA-repairing  enzymes  (51-55),  and  therefore  accumu- 
late  mutations possibly generating new antigenic  peptides, 
suggests that such unique antigens may be frequently present 
on human tumors. It is not impossible that future technical 
improvements will allow the design of individually specific 
vaccines based on defined unique antigens. 
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